BioCatalystWatch
GLPGWorkspace / GLPG / OverviewCompany library
Price
Market cap
Next catalystDec 13, 2026Gamgertamig — OM336-AIC-1001 · Phase 1 dataCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

BCMA × CD3

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

BCMA × CD3

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Other pipelines

gamgertamig (OM336)

BCMA × CD3

TYK2 '3667

TYK2

PreINDP1P2P3FilingApproved
TYK2 '3667

TYK2

TYK2 molecule

TYK2

PreINDP1P2P3FilingApproved

Partner / License out

History / paused

BCMA

PreINDP1P2P3FilingApproved

CD19

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

GLPG PR & News

PR & News

GLPG SEC archive